spacer
spacer

PDBsum entry 1hii

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Hydrolase (aspartic proteinase) PDB id
1hii

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
99 a.a. *
Ligands
SO4 ×2
C20
Waters ×194
* Residue conservation analysis
PDB id:
1hii
Name: Hydrolase (aspartic proteinase)
Title: Comparative analysis of the x-ray structures of HIV-1 and HIV-2 proteases in complex with cgp 53820, a novel pseudosymmetric inhibitor
Structure: HIV-2 protease. Chain: a, b. Engineered: yes
Source: Human immunodeficiency virus 2. Organism_taxid: 11709. Cell_line: s2. Gene: pol. Expressed in: escherichia coli. Expression_system_taxid: 562.
Biol. unit: Dimer (from PQS)
Resolution:
2.30Å     R-factor:   0.138    
Authors: J.P.Priestle,M.G.Gruetter
Key ref:
J.P.Priestle et al. (1995). Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure, 3, 381-389. PubMed id: 7613867 DOI: 10.1016/S0969-2126(01)00169-1
Date:
31-Mar-95     Release date:   10-Jul-95    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
P04584  (POL_HV2RO) -  Gag-Pol polyprotein from Human immunodeficiency virus type 2 subtype A (isolate ROD)
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1464 a.a.
99 a.a.
Key:    Secondary structure  CATH domain

 Enzyme reactions 
   Enzyme class 1: E.C.2.7.7.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 2: E.C.2.7.7.49  - RNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 3: E.C.2.7.7.7  - DNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 4: E.C.3.1.-.-
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 5: E.C.3.1.13.2  - exoribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
   Enzyme class 6: E.C.3.1.26.13  - retroviral ribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 7: E.C.3.4.23.47  - HIV-2 retropepsin.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
DOI no: 10.1016/S0969-2126(01)00169-1 Structure 3:381-389 (1995)
PubMed id: 7613867  
 
 
Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor.
J.P.Priestle, A.Fässler, J.Rösel, M.Tintelnot-Blomley, P.Strop, M.G.Grütter.
 
  ABSTRACT  
 
BACKGROUND: The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). Two subtypes of the virus, HIV-1 and HIV-2, have been characterized. The protease enzymes from these two subtypes, which are aspartic acid proteases and have been found to be essential for maturation of the infectious particle, share about 50% sequence identity. Differences in substrate and inhibitor binding between these enzymes have been previously reported. RESULTS: We report the X-ray crystal structures of both HIV-1 and HIV-2 proteases each in complex with the pseudosymmetric inhibitor, CGP 53820, to 2.2 A and 2.3 A, respectively. In both structures, the entire enzyme and inhibitor could be located. The structures confirmed earlier modeling studies. Differences between the CGP 53820 inhibitory binding constants for the two enzymes could be correlated with structural differences. CONCLUSIONS: Minor sequence changes in subsites at the active site can explain some of the observed differences in substrate and inhibitor binding between the two enzymes. The information gained from this investigation may help in the design of equipotent HIV-1/HIV-2 protease inhibitors.
 
  Selected figure(s)  
 
Figure 2.
Figure 2. The pseudosymmetrical HIV protease inhibitor CGP 53820. Cha refers to the cyclohexyl ‘side chain’ which binds in the P1′ pocket of HIV protease. Figure 2. The pseudosymmetrical HIV protease inhibitor CGP 53820. Cha refers to the cyclohexyl ‘side chain’ which binds in the P1′ pocket of HIV protease.
Figure 6.
Figure 6. Stereo illustration of the binding of CGP 53820 (green) to HIV-1 protease (red) superimposed with HIV-2 protease (blue) in complex with CGP 53820 (yellow). Figure 6. Stereo illustration of the binding of CGP 53820 (green) to HIV-1 protease (red) superimposed with HIV-2 protease (blue) in complex with CGP 53820 (yellow).
 
  The above figures are reprinted by permission from Cell Press: Structure (1995, 3, 381-389) copyright 1995.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
15280771 F.Ceccherini-Silberstein, F.Erba, F.Gago, A.Bertoli, F.Forbici, M.C.Bellocchi, C.Gori, R.D'Arrigo, L.Marcon, C.Balotta, A.Antinori, A.D.Monforte, and C.F.Perno (2004).
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure.
  AIDS, 18, F11-F19.  
14766818 P.Colson, M.Henry, C.Tourres, D.Lozachmeur, H.Gallais, J.A.Gastaut, J.Moreau, and C.Tamalet (2004).
Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.
  J Clin Microbiol, 42, 570-577.  
14702957 A.Raja, J.Lebbos, and P.Kirkpatrick (2003).
Atazanavir sulphate.
  Nat Rev Drug Discov, 2, 857-858.  
  10747109 B.Rodés, A.Holguín, V.Soriano, M.Dourana, K.Mansinho, F.Antunes, and J.González-Lahoz (2000).
Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.
  J Clin Microbiol, 38, 1370-1374.  
  11106162 L.Hong, X.C.Zhang, J.A.Hartsuck, and J.Tang (2000).
Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
  Protein Sci, 9, 1898-1904.
PDB code: 1fb7
10739910 S.Munshi, Z.Chen, Y.Yan, Y.Li, D.B.Olsen, H.B.Schock, B.B.Galvin, B.Dorsey, and L.C.Kuo (2000).
An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease.
  Acta Crystallogr D Biol Crystallogr, 56, 381-388.
PDB codes: 1c6x 1c6y 1c6z 1c70
9485411 R.B.Rose, C.S.Craik, and R.M.Stroud (1998).
Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
  Biochemistry, 37, 2607-2621.
PDB code: 1az5
9136873 E.M.Towler, S.K.Thompson, T.Tomaszek, and C.Debouck (1997).
Identification of a loop outside the active site cavity of the human immunodeficiency virus proteases which confers inhibitor specificity.
  Biochemistry, 36, 5128-5133.  
8756683 S.S.Hoog, E.M.Towler, B.Zhao, M.L.Doyle, C.Debouck, and S.S.Abdel-Meguid (1996).
Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.
  Biochemistry, 35, 10279-10286.
PDB codes: 1tcw 1tcx
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.

 

spacer

spacer